{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037893","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.503290+00:00","generated_at":"2026-06-08T10:03:47.347523+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TOI reports Q3 revenue $82M (+26% YoY), net loss widens to $17.4M from $2.7M","bullets":["Revenue $82M (+26% YoY); gross profit $16M (+23% YoY); gross margin 19.5% (down from 20.0%).","Net loss $17.4M ($0.19 diluted loss) vs $2.7M loss ($0.03 loss) prior year; Adjusted EBITDA loss $(5.3)M vs $(6.7)M.","Cash and investments $87.4M as of Sept 30, 2023.","Opened 70th clinic, added 5 physicians (total 112); signed full-risk capitated contract in South Florida effective Jan 1, 2024.","Reaffirmed full year 2023 guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037893","json":"https://secwatch.observer/filing/0001628280-23-037893.json","markdown":"https://secwatch.observer/filing/0001628280-23-037893.md","text":"https://secwatch.observer/filing/0001628280-23-037893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023037893/0001628280-23-037893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023037893/toi-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:03:47.347523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f451950b6360119fd922724fe770d53312f1b4e2","claim":"Oncology Institute, Inc. reported three months ended September 30, 2023 results: revenue $82 million, net income Net loss of $17.4 million, EPS $(0.19). Guidance reaffirmed.","evidence_excerpt":"new Chief Operating Officer • Signed full-risk capitated contract in South Florida, effective January 1, 2024 Third Quarter 2023 Financial Highlights • Consolidated revenue of $82 million, an increase of 26% compared to the prior year quarter • Gross profit of $16 million, an increase of 23% compared to the prior year quarter, and gross margin of 19.5%, a decrease","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023037893/0001628280-23-037893-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Revenue","value":"$82 million"},{"label":"Net income","value":"Net loss of $17.4 million"},{"label":"EPS","value":"$(0.19)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}